The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.

Phase 2 Completed 80 enrolled Hospital Civil de Guadalajara

RandomizedParallel-groupDouble-blindTreatment

In double-blind clinical trial, determine renal recovery with two different furosemide strategies in patients with type 1 cardiorenal syndrome.

Evaluation	Drug	Modality	Dose	Route
Subject	Chlortalidone	Unknown	50 mg	Oral
Subject	Furosemide	Other / unclassified	80 mg	Intravenous
Subject	Furosemide	Other / unclassified	100 mg	Intravenous
Subject	Furosemide	Other / unclassified	400 mg	Intravenous
Subject	Spironolactone	Small molecule	50 mg	Oral